ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B... ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression.
- Mechanism
- Curator reviewed
ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC). pDC and IFN-alpha and -beta then induce natural killer (NK) cell proliferation, NK cell production of IFN-gamma, and NK cell-mediated cytotoxicity. Secreted IFNs also stimulate bystander T cell activation and differentiation of naive CD4+ T cells into T-helper 1 cells on specific antigen challenge.
- Primary indication
- Investigated for use/treatment in colorectal cancer, hepatitis (viral, B), and lymphoma (non-hodgkin's).Curator reviewed
- Code names
- 1018 ISS · CPG-1018 · ISS-1018 · ISS 1018 CpG ODN
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with ISS-1018, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account